Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Holdings Lifted by AQR Capital Management LLC

AQR Capital Management LLC grew its position in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 494.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 748,020 shares of the company’s stock after purchasing an additional 622,194 shares during the period. AQR Capital Management LLC owned approximately 0.60% of Karyopharm Therapeutics worth $649,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Ikarian Capital LLC grew its position in Karyopharm Therapeutics by 2.3% in the 1st quarter. Ikarian Capital LLC now owns 409,355 shares of the company’s stock worth $618,000 after purchasing an additional 9,355 shares during the last quarter. Point72 DIFC Ltd bought a new position in shares of Karyopharm Therapeutics in the second quarter valued at approximately $31,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Karyopharm Therapeutics in the second quarter valued at approximately $143,000. Acadian Asset Management LLC bought a new position in shares of Karyopharm Therapeutics in the second quarter valued at approximately $167,000. Finally, Cubist Systematic Strategies LLC bought a new position in shares of Karyopharm Therapeutics in the second quarter valued at approximately $494,000. Institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Trading Up 1.7 %

NASDAQ KPTI opened at $0.86 on Monday. The firm’s fifty day moving average price is $0.79 and its two-hundred day moving average price is $0.96. Karyopharm Therapeutics Inc. has a 1 year low of $0.62 and a 1 year high of $1.95. The firm has a market capitalization of $107.32 million, a P/E ratio of -0.68 and a beta of 0.20.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.09. The business had revenue of $42.79 million during the quarter, compared to analyst estimates of $36.07 million. On average, research analysts anticipate that Karyopharm Therapeutics Inc. will post -0.93 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on KPTI. StockNews.com upgraded shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Royal Bank of Canada restated an “outperform” rating and set a $3.00 target price on shares of Karyopharm Therapeutics in a report on Wednesday, August 7th. Robert W. Baird reduced their price target on shares of Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating for the company in a research report on Wednesday, August 7th. Finally, HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Karyopharm Therapeutics in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $4.80.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).